Philadelphia, Pennsylvania, USA.
Psychiatry and Neurology, Washington University of St. Louis School of Medicine, St Louis, Missouri, USA.
Alzheimers Dement. 2024 Nov;20(11):8188-8191. doi: 10.1002/alz.14256. Epub 2024 Oct 6.
A brief history of events surrounding the conceptualization and original implementation of the Alzheimer's Disease Neuroimaging Initiative (ADNI) as a public-private partnership (PPP) is provided from the perspective of three individuals directly involved from the outset. Potential barriers and how they were addressed are summarized, especially the decision to make all data freely accessible in real-time. Decisions made at the beginning of ADNI are revisited in light of what has been learned over the past 20 years, especially the importance of the investment in cerebrospinal fluid (CSF) and blood measures and the commitment to data sharing. The key elements of ADNI's success from the authors' perspective are also summarized. HIGHLIGHTS: Informal interactions among colleagues were the beginning of something big. An NIH Director's personal decision on open data sharing has had perhaps the greatest impact of any single decision in the past several decades in terms of advancing clinical biomarker research. After 20 years, blood-based biomarkers of brain disease may soon take the place of brain imaging for purposes of diagnosis and drug development.
提供了从三位直接参与最初合作的人员的角度,简要回顾了阿尔茨海默病神经影像学倡议 (ADNI) 作为公私合作伙伴关系 (PPP) 的构想和最初实施的相关事件。总结了潜在的障碍以及如何解决这些障碍的方法,特别是做出实时免费提供所有数据的决定。根据过去 20 年所学到的知识,重新审视了 ADNI 成立之初的决策,特别是对脑脊液 (CSF) 和血液检测投入的重要性,以及对数据共享的承诺。还总结了作者认为 ADNI 成功的关键因素。
要点:
同事之间的非正式互动是重要的开始。
NIH 主任关于开放数据共享的个人决策可能是过去几十年中在推进临床生物标志物研究方面最具影响力的单一决策。
20 年后,用于诊断和药物开发的脑成像可能很快会被基于血液的脑疾病生物标志物所取代。